{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:59:01Z","timestamp":1781078341471,"version":"3.54.1"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Anti-EGFR monoclonal antibodies (mAbs)--cetuximab, panitumumab, and necitumumab--are cornerstone therapies for selected solid tumors but are frequently associated with cutaneous adverse drug reactions (ADRs). This study aimed to characterize and compare the dermatologic safety profiles of these agents using large-scale post-marketing pharmacovigilance data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive pharmacovigilance analysis was conducted using aggregated ADR reports from the WHO VigiAccess and European Medicines Agency (EMA) EudraVigilance databases. Disproportionality analyses were performed using reporting odds ratios (RORs) and proportional reporting ratios (PRRs). Dermatologic ADR diversity and similarity were further evaluated using Shannon entropy, principal component analysis (PCA), and multidimensional scaling (MDS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 50,391, 18,806, and 355 ADR reports were identified for cetuximab, panitumumab, and necitumumab, respectively. Cutaneous ADRs accounted for up to 25% of all reported events. Panitumumab demonstrated the strongest association with skin-related toxicities (ROR = 1.51; PRR = 1.38), particularly acneiform dermatitis, pruritus, and xerosis. Cetuximab exhibited lower relative disproportionality despite higher absolute numbers of reported cases, whereas necitumumab showed a narrower dermatologic toxicity profile, potentially reflecting lower utilization or underreporting. Shannon entropy and dimensionality reduction analyses revealed greater heterogeneity of dermatologic ADRs associated with panitumumab compared with cetuximab and necitumumab. Significant differences in ADR distributions were observed between the WHO and EMA databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings highlight distinct agent-specific dermatologic toxicity signatures among anti-EGFR monoclonal antibodies and demonstrate the value of real-world pharmacovigilance data in complementing clinical trial evidence. Improved recognition of differential toxicity patterns may support personalized monitoring and management strategies for patients receiving EGFR-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1791359","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:15:36Z","timestamp":1781075736000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess"],"prefix":"10.3389","volume":"17","author":[{"given":"Natalia","family":"Sauer","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmacy, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Giedziun","sequence":"additional","affiliation":[{"name":"Department of Artificial Intelligence, Wroclaw University of Science and Technology","place":["Wroc\u0142aw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Calik","sequence":"additional","affiliation":[{"name":"Old Town Clinic","place":["Wroc\u0142aw, Poland"]},{"name":"Division of Histology and Embryology, Department of Human Morphology and Embryology, Faculty of Medicine, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wiela-Hoje\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Pharmacy, Wroclaw Medical University","place":["Wroclaw, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"485","DOI":"10.21037\/jgo.2017.01.07","article-title":"Biological agents in gastrointestinal cancers: adverse effects and their management","volume":"8","author":"Arora","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1158\/1535-7163.MCT-17-0575","article-title":"Molecular basis for necitumumab inhibition of EGFR variants associated with acquired cetuximab resistance","volume":"17","author":"Bagchi","year":"2018","journal-title":"Mol. Cancer Therapeutics"},{"key":"B3","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula","year":"2010","journal-title":"J. Support. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/life12010048","article-title":"Comparison of anticancer drug toxicities: Paradigm shift in adverse effect profile","volume":"12","author":"Basak","year":"2021","journal-title":"Life Basel, Switz."},{"key":"B5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.jaad.2014.06.011","article-title":"Managing skin toxicities related to panitumumab","volume":"71","author":"Bergman","year":"2014","journal-title":"J. Am. Acad. Dermatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1470-2045(09)70311-0","article-title":"Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival","volume":"11","author":"Bonner","year":"2010","journal-title":"Lancet Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.3748\/wjg.v25.i29.4007","article-title":"Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer","volume":"25","author":"Bouch\u00e9","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/1078155216682365","article-title":"Necitumumab for the treatment of squamous cell non-small cell lung cancer","volume":"24","author":"Brinkmeyer","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B9","first-page":"21","article-title":"Rola farmaceuty w opiece nad pacjentem z chorob\u0105 nowotworow\u0105","volume":"8","author":"Burak","year":"2015","journal-title":"Farm. Wsp\u00f3\u0142czesna"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.abd.2020.01.001","article-title":"Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel","volume":"95","author":"Cury-Martins","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s11307-013-0652-9","article-title":"Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma","volume":"15","author":"Day","year":"2013","journal-title":"Mol. Imaging Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jnci\/djp439","article-title":"Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy","volume":"102","author":"Eilers","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"B14","volume-title":"ERBITUX (cetuximab) [prescribing information]","year":"2024"},{"key":"B68","unstructured":"Amsterdam\n          European Medicines Agency\n          Portrazza (necitumumab): Summary of Product Characteristics (SmPC)\n          \n          2016"},{"key":"B15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000371821","article-title":"Acneiform rash induced by EGFR inhibitors: review of the literature and new insights","volume":"1","author":"Fabbrocini","year":"2015","journal-title":"Skin. Appendage Disorders"},{"key":"B16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4161\/mabs.29089","article-title":"Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer","volume":"6","author":"Fauvel","year":"2014","journal-title":"mAbs"},{"key":"B17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11096-018-0653-5","article-title":"Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilance","volume":"40","author":"Fornasier","year":"2018","journal-title":"Int. Journal Clinical Pharmacy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s40780-024-00403-4","article-title":"Pharmacist intervention and identification of adverse events related to treatment efficacy in cancer chemotherapy to improve clinical outcomes","volume":"10","author":"Fujii","year":"2024","journal-title":"J. Pharm. Health Care Sci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3389\/fonc.2019.00849","article-title":"Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors","volume":"9","author":"Garc\u00eda-Foncillas","year":"2019","journal-title":"Front. Oncology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s40266-023-01064-y","article-title":"Systematic review and meta-analysis of interventions to reduce adverse drug reactions in older adults: an update","volume":"40","author":"Gray","year":"2023","journal-title":"Drugs & Aging"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"104586","DOI":"10.1016\/j.critrevonc.2024.104586","article-title":"Comprehensive review of signaling pathways and therapeutic targets in gastrointestinal cancers","volume":"206","author":"Ji","year":"2025","journal-title":"Crit. Reviews Oncology\/hematology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.7150\/ijms.122194","article-title":"Real-world safety of anti-egfr antibodies: 20-year pharmacovigilance of cetuximab and panitumumab","volume":"22","author":"Jin","year":"2025","journal-title":"Int. J. Med. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e5853","DOI":"10.1002\/pds.5853","article-title":"Association of pharmacist interventions with adverse drug events and potential adverse drug events","volume":"33","author":"Kelly","year":"2024","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5114\/wo.2013.38566","article-title":"Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer","volume":"18","author":"Krawczyk","year":"2014","journal-title":"Contemp. Oncology\/Wsp\u00f3\u0142czesna Onkol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","year":"2011","journal-title":"Support. Care Cancer Official J. Multinatl. Assoc. Support. Care Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clcc.2017.12.004","article-title":"Dermatologic toxicity occurring during Anti-EGFR monoclonal inhibitor therapy in patients with metastatic colorectal cancer: a systematic review","volume":"17","author":"Lacouture","year":"2018","journal-title":"Clin. Colorectal Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/bcp.16266","article-title":"Economic burden of hospital admissions for adverse drug reactions in France: the IATROSTAT-ECO study","volume":"91","author":"Laroche","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e968","DOI":"10.1634\/theoncologist.2018-0476","article-title":"Adverse drug reactions in an oncological population: prevalence, predictability, and preventability","volume":"24","author":"Lavan","year":"2019","journal-title":"Oncologist"},{"key":"B69","doi-asserted-by":"publisher","first-page":"adv40555","DOI":"10.2340\/actadv.v104.40555","article-title":"Skin toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitors and their influence on treatment adjustments in lung cancer patients","volume":"104","author":"Lee","year":"2024","journal-title":"Acta. Derm. Venereol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"804212","DOI":"10.3389\/fonc.2022.804212","article-title":"Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies","volume":"12","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40262-016-0452-x","article-title":"Population pharmacokinetics of necitumumab in cancer patients","volume":"56","author":"Long","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"47777","DOI":"10.18632\/oncotarget.10013","article-title":"Epidermal growth factor receptor inhibitors trigger a type I interferon response in human skin","volume":"7","author":"Lulli","year":"2016","journal-title":"Oncotarget"},{"key":"B33","doi-asserted-by":"publisher","first-page":"178278","DOI":"10.1016\/j.ejphar.2025.178278","article-title":"Postmarketing safety signals of cetuximab and panitumumab in the FAERS database: real-world insights focus on population heterogeneity","volume":"1007","author":"Mao","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","article-title":"Epidermal growth factor receptor (EGFR) signaling in cancer","volume":"366","author":"Normanno","year":"2006","journal-title":"Gene"},{"key":"B36","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/S1470-2045(15)70046-X","article-title":"Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study","volume":"16","author":"Paz-Ares","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000486338","article-title":"Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis","volume":"94","author":"Petrelli","year":"2018","journal-title":"Oncology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S1470-2045(14)70118-4","article-title":"Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study","volume":"15","author":"Price","year":"2014","journal-title":"Lancet Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e18470","DOI":"10.1111\/jcmm.18470","article-title":"Immune-related adverse events of antibody-based biological medicines in cancer therapy","volume":"28","author":"Rajagopal","year":"2024","journal-title":"J. Cellular Molecular Medicine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1470-2045(05)70243-6","article-title":"Cutaneous side-effects of kinase inhibitors and blocking antibodies","volume":"6","author":"Robert","year":"2005","journal-title":"Lancet. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1158\/1535-7163.MCT-18-0341","article-title":"Immune effector functions of human IgG2 antibodies against EGFR. Immune effector functions of human IgG2 antibodies against EGFR","volume":"18","author":"R\u00f6sner","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/14740338.6.2.175","article-title":"Incidence and management of cutaneous toxicities associated with cetuximab","volume":"6","author":"Saif","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"B44","doi-asserted-by":"publisher","first-page":"512","DOI":"10.4049\/jimmunol.0900847","article-title":"Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage","volume":"184","author":"Schneider-Merck","year":"2010","journal-title":"J. Immunol. Baltim. Md. 1950"},{"key":"B45","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors","volume":"16","author":"Segaert","year":"2005","journal-title":"Ann. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.3892\/or.2014.3077","article-title":"Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer","volume":"31","author":"Seo","year":"2014","journal-title":"Oncol. Rep."},{"key":"B47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Sig Transduct. Target Ther."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0163366","DOI":"10.1371\/journal.pone.0163366","article-title":"The panitumumab EGFR complex reveals a binding mechanism that overcomes cetuximab induced resistance","volume":"11","author":"Sickmier","year":"2016","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/1878-0261.12155","article-title":"Emerging functions of the EGFR in cancer","volume":"12","author":"Sigismund","year":"2018","journal-title":"Mol. Oncology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","article-title":"Pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Segaert S, Van cutsem E","volume":"16","author":"Signs","year":"2005","journal-title":"Ann. Oncol. Official J. Eur. Soc. Med. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systematic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"B52","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin vs. gemcitabine and cisplatin alone in squamous NSCLC (SQUIRE): a phase 3 trial","volume":"16","author":"Thatcher","year":"","journal-title":"Lancet Oncol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"","journal-title":"Lancet Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Sig Transduct. Target Ther."},{"key":"B55","first-page":"3","article-title":"Pharmacist participation in the reduction of preventable adverse drug reactions in Thai hospitalised patients","volume":"7","author":"Tragulpiankit","year":"2009","journal-title":"J. Appl. Ther. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1152\/physiolgenomics.00176.2011","article-title":"EGFR regulation of epidermal barrier function","volume":"44","author":"Tran","year":"2012","journal-title":"Physiol. Genomics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5229","DOI":"10.1158\/1078-0432.CCR-15-2971","article-title":"Anti-Egfr targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients","volume":"22","author":"Trivedi","year":"2016","journal-title":"Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s00520-020-05875-2","article-title":"Skin disorder management in oral anticancer drugs by collaboration of hospital pharmacists and community pharmacists","volume":"29","author":"Urakawa","year":"2021","journal-title":"Support Care Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1593\/neo.121242","article-title":"Functional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximab","volume":"14","author":"Voigt","year":"2012","journal-title":"Neoplasia (New York, N.Y.)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"B63","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.esmoop.2024.102975","article-title":"Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM","volume":"9","author":"Watanabe","year":"2024","journal-title":"ESMO Open"},{"key":"B64","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2165\/11535970-000000000-00000","article-title":"Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab","volume":"49","author":"Yang","year":"2010","journal-title":"Clin. Pharmacokinet."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamadermatol.2020.1795","article-title":"Evaluation of a comprehensive skin toxicity program for patients treated with epidermal growth factor receptor inhibitors at a cancer treatment center","volume":"156","author":"Yu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1124\/pharmrev.123.000906","article-title":"Targeting epidermal growth factor receptor for cancer treatment: abolishing both kinase-dependent and kinase-independent functions of the receptor","volume":"75","author":"Zhang","year":"2023","journal-title":"Pharmacol. Rev."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1791359\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:15:39Z","timestamp":1781075739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1791359\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":67,"alternative-id":["10.3389\/fphar.2026.1791359"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1791359","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"article-number":"1791359"}}